Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Oncocyte Corporation (OCX:NASDAQ), powered by AI.
Oncocyte Corporation is currently trading at $3.76. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Oncocyte Corporation on Alpha Lenz.
Oncocyte Corporation's P/E ratio is -0.8.
“Oncocyte Corporation trades at a P/E of -0.8 (undervalued) with modest ROE of -1480.7%.”
Ask for details →Oncocyte Corporation is a biotechnology company focused on the development of molecular diagnostic tests for the detection of cancer. The primary function of Oncocyte is to improve patient outcomes by enhancing cancer diagnosis and monitoring through advanced genomic testing technologies. Its tests are designed to empower physicians with precise information, enabling more informed decisions regarding cancer treatment and management. Operating in the healthcare sector, Oncocyte plays a vital role in the fields of oncology and precision medicine, as it works towards personalized treatment options. The company’s mission is also to address the limitations of existing diagnostic methods by providing more accurate and less invasive alternatives. With a commitment to research and innovation, Oncocyte's offerings have the potential to significantly impact the early detection and treatment efficacy of various cancers. By focusing on unmet needs in the cancer diagnosis landscape, Oncocyte Corporation contributes to the broader healthcare market in efforts to improve patient care and clinical outcomes.
“Oncocyte Corporation trades at a P/E of -0.8 (undervalued) with modest ROE of -1480.7%.”
Ask for details →